2月25日，博雅生物涨0.59%，成交额7261.74万元。两融数据显示，当日博雅生物获融资买入额1233.54 万元，融资偿还972.60万元，融资净买入260.94万元。截至2月25日，博雅生物融资融券余额合计6.86亿 元。 机构持仓方面，截止2025年9月30日，博雅生物十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股888.43万股，相比上期减少1815.54万股。招商国证生物医药指数A（161726）位居第六大 流通股东，持股434.18万股，相比上期减少75.06万股。 融资方面，博雅生物当日融资买入1233.54万元。当前融资余额6.83亿元，占流通市值的6.07%，融资余 额超过近一年80%分位水平，处于高位。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 融券方面，博雅生物2月25日融券偿还1900.00股，融券卖出4000.00股，按当日收盘价计算，卖出金额 8.92万元；融券余量12.23万股， ...

2月24日，山东科源制药股份有限公司（简称"科源制药"）发布2025年度业绩预告修正公告，将归母净 利润预期从同比下降35%-55%大幅下修至下降70%-80%，预计全年归母净利润仅1208.97万元至1813.45 万元。这场业绩"跳水"的直接导火索，是子公司一桩突如其来的合同纠纷诉讼。 公告显示，科源制药子公司山东力诺制药有限公司（简称"力诺制药"）于2月14日收到江苏省灌南县人 民法院《民事判决书》，就其与江苏赛邦药业有限公司的销售代理合同纠纷一案作出一审判决。依据该 判决，力诺制药需承担赔偿责任1610.70万元，该事项属于资产负债表日后调整事项，是公司无法合理 预见的事项，因此公司需对2025年度业绩预告情况作出修正：确认营业外支出约1610.70万元，同时相 应减少归属于上市公司股东的净利润。 科源制药认为，此次业绩修正源于上述判决对公司非经常性损益项目的影响，影响金额预计约1610.70 万元。业绩修正后，科源制药预计归母净利润为1208.97万元至1813.45万元，比上年同期下降70%至 80%。此前，科源制药预计归母净利润为盈利2720.19万元至3929.16万元，比上年同期下降35%至 ...

Group 1 - The core point of the article highlights the recent performance of Zhongguancun (000931), which closed at 5.3 yuan on February 9, 2026, with a 1.92% increase and a turnover rate of 2.12% [1] - The stock experienced a net inflow of main funds amounting to 11.89 million yuan, representing 14.15% of the total transaction amount, while retail investors saw a net outflow of 9.45 million yuan, accounting for 11.23% of the total [1] - For the first three quarters of 2025, Zhongguancun reported a main revenue of 1.882 billion yuan, a year-on-year decrease of 2.46%, and a net profit attributable to shareholders of 49.49 million yuan, down 4.14% year-on-year [1] Group 2 - The company’s main business segments include biopharmaceuticals and health products, elderly medical services, commercial concrete, and other businesses [1] - The biopharmaceutical and health products segment involves the research, manufacturing, and sales of various pharmaceutical forms, including chemical drugs, traditional Chinese medicine, and medical devices [1] - The elderly medical services segment encompasses centralized elderly care, home care services, health management, and internet hospital services [1]

中关村2025年三季报显示，前三季度公司主营收入18.82亿元，同比下降2.46%；归母净利润4949.14万 元，同比下降4.14%；扣非净利润4364.42万元，同比上升8.99%；其中2025年第三季度，公司单季度主 营收入6.44亿元，同比下降1.96%；单季度归母净利润1068.25万元，同比下降29.9%；单季度扣非净利 润678.93万元，同比下降47.83%；负债率51.09%，投资收益-168.26万元，财务费用3613.22万元，毛利 率59.64%。中 关 村（000931）主营业务：业务主要分为生物医药及健康品业务、养老医疗业务、商砼 业务和其他业务。其中:1、生物医药及健康品业务包括化学药、中药、健康品和医疗器械业务,主要从 事外用制剂、片剂、注射剂、胶囊、口服溶液剂、颗粒剂、原料药、麻醉药品及二类精神药品的研发、 制造与销售;药品临床前研究服务及药品一致性评价研究服务;医疗设备、试剂和相关耗材的销售及服务 业务;口腔清洁用品的研发、生产与销售;2、养老医疗业务主要包括集中养老服务、居家养老服务、健 康管理、健康咨询、预防保健咨询、中医医疗服务、养老旅居业务以及依托实体医院的互联网医 ...

Core Viewpoint - The financial performance and trading activity of Boya Bio-Pharmaceutical Co., Ltd. indicate a mixed outlook, with a notable increase in revenue but a decline in net profit, alongside significant trading volumes in both margin financing and securities lending [1][2]. Group 1: Financial Performance - For the period from January to September 2025, Boya Bio achieved a revenue of 1.474 billion yuan, representing a year-on-year growth of 18.38% [2]. - The net profit attributable to shareholders for the same period was 343 million yuan, which reflects a year-on-year decrease of 16.90% [2]. - Cumulatively, the company has distributed a total of 1.007 billion yuan in dividends since its A-share listing, with 489 million yuan distributed over the past three years [3]. Group 2: Trading Activity - On January 30, Boya Bio's stock price decreased by 0.86%, with a trading volume of 137 million yuan [1]. - The margin financing data for January 30 shows a buying amount of 17.01 million yuan and a repayment of 18.94 million yuan, resulting in a net margin buy of -1.93 million yuan [1]. - The total margin financing and securities lending balance as of January 30 was 684 million yuan, with the margin balance accounting for 5.89% of the circulating market value, indicating a high level compared to the past year [1].

证券日报网讯1月28日，一品红（300723）在互动平台回答投资者提问时表示，一品红是一家集药品研 发、生产、销售为一体的创新型生物医药企业，聚焦于儿童药和慢病药领域；目前，公司具备医药全产 业链的研发运营管理能力，产品涵盖范围包括化学药(含制剂和原料药)、中(成)药等领域。 ...

1月28日的资金流向数据方面，主力资金净流出131.81万元，占总成交额2.8%，游资资金净流入63.4万 元，占总成交额1.35%，散户资金净流入68.4万元，占总成交额1.45%。 | 指标 | 中关村 | 化学制药行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 38.79亿元 | 142.59亿元 | 116 146 | | 净资产 | 18.66亿元 | 51.14亿元 | 87 146 | | 净利润 | 4949.14万元 | 3.18亿元 | 90 146 | | 市盈率(动) | 58.78 | 29.37 | 83 146 | | 市净率 | 2.37 | 5.64 | 55 146 | | 毛利率 | 59.64% | 48.84% | 46 146 | | 净利率 | 3.25% | 5.61% | 96 146 | | ROE | 3.07% | 2.83% | 90 146 | 证券之星消息，截至2026年1月28日收盘，中 关 村(000931)报收于5.15元，下跌1.15%，换手率1.21%， 成交量9.1万手，成交额4702.6 ...

Group 1 - The core viewpoint of the news is that Tai Long Pharmaceutical has shown a significant increase in trading activity, with a 2.69% rise in stock price and a trading volume of 188 million yuan on January 23 [1] - As of January 23, the financing balance of Tai Long Pharmaceutical reached 290 million yuan, accounting for 7.35% of its market capitalization, indicating a high level of financing activity compared to the past year [1] - The company has a diverse revenue structure, with 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [1] Group 2 - As of September 30, the number of shareholders for Tai Long Pharmaceutical was 40,400, a decrease of 1.08% from the previous period, while the average circulating shares per person increased by 1.09% to 14,190 shares [2] - For the period from January to September 2025, Tai Long Pharmaceutical reported a revenue of 1.187 billion yuan, a year-on-year decrease of 11.47%, and a net profit attributable to shareholders of 25.33 million yuan, down 12.36% year-on-year [2] - The company has distributed a total of 120 million yuan in dividends since its A-share listing, with 23.27 million yuan distributed over the past three years [3]

Group 1 - The stock of Zhongguancun (000931) closed at 5.17 yuan on January 22, 2026, with an increase of 1.37% and a turnover rate of 1.68% [1] - The trading volume was 126,400 hands, with a total transaction amount of 65.031 million yuan [1] - On January 22, the net inflow of main funds was 3.0816 million yuan, accounting for 4.74% of the total transaction amount, while retail funds had a net outflow of 4.7124 million yuan, accounting for 7.25% [1] Group 2 - For the first three quarters of 2025, Zhongguancun reported a main operating income of 1.882 billion yuan, a year-on-year decrease of 2.46%, and a net profit attributable to shareholders of 49.4914 million yuan, down 4.14% year-on-year [2] - The third quarter of 2025 saw a single-quarter main operating income of 644 million yuan, a decrease of 1.96% year-on-year, and a net profit attributable to shareholders of 10.6825 million yuan, down 29.9% year-on-year [2] - The company has a debt ratio of 51.09%, with investment income of -1.6826 million yuan and financial expenses of 36.1322 million yuan, while the gross profit margin stands at 59.64% [2] Group 3 - Zhongguancun's main business segments include biopharmaceuticals and health products, elderly medical care, commercial concrete, and other businesses [2] - The biopharmaceutical and health products segment involves the research, manufacturing, and sales of various pharmaceutical forms, including chemical drugs, traditional Chinese medicine, and medical devices [2] - The elderly medical care segment encompasses centralized elderly care services, home care services, health management, and traditional Chinese medical services [2]

Group 1 - The core point of the news is that Zhongsheng Pharmaceutical's stock price has dropped by 5.26%, currently trading at 20.90 CNY per share, with a total market capitalization of 17.764 billion CNY [1] - Zhongsheng Pharmaceutical, established on December 31, 2001, and listed on December 11, 2009, is primarily engaged in the research, production, and sales of pharmaceuticals [1] - The company's revenue composition includes 53.03% from traditional Chinese medicine sales, 38.12% from chemical drug sales, 6.13% from Chinese medicinal materials and decoction pieces, 2.14% from raw materials and intermediates, and 0.58% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Taixin Fund has a significant position in Zhongsheng Pharmaceutical, with Taixin Smart Quantitative Stock Mixed Fund A (013033) holding 15,000 shares, accounting for 1.94% of the fund's net value [2] - The estimated floating loss for the fund today is approximately 17,400 CNY [2] - Taixin Smart Quantitative Stock Mixed Fund A (013033) was established on May 22, 2025, with a current scale of 12.5156 million CNY and a year-to-date return of 8.16%, ranking 1626 out of 8844 in its category [2]